Morphological changes induced by insulin-like growth factor-I gene therapy in pituitary cell populations in experimental prolactinomas by Camihort, Gisela et al.
Original Paper
Cells 
Tissues
Organs
Cells Tissues Organs 2010;191:316-325
DOI: 10.1159/000258701
Accepted after revision: July 30, 2009
Published online: November 14, 2009
Morphological Changes Induced by Insulin-Like 
Growth Factor-I Gene Therapy in Pituitary Cell 
Populations in Experimental Prolactinomas
Gisela A. Camihort3 Claudia B. Herenub Georgina C. Lunac Silvia S. Rodrfguezb
Maria I. Bracamonte3 Rodolfo G. Goyab Gloria M. Console3, c
a Department of Cytology, Histology and Embryology B, b INI BIOLP, Faculty of Medicine, National University of 
La Plata, and CCICPBA, La Plata, Argentina
Key Words
Insulin-like growth factor type I • Prolactinomas • Pituitary 
cell populations • Gene therapy • Estrogen • Rat
Abstract
In previous studies, we assessed the effects of intra pituitary 
injection of a recombinant adenoviral vector (RAd) harbor­
ing the cDNA for rat insulin-like growth factor type I (RAd- 
IGF-I) on the lactotrope and somatotrope populations in es­
trogen-induced prolactinomas. In the present study, we 
aimed to confirm these findings and further analyze the ef­
fect of transgenic RAd-IGF-l on the other pituitary cell popu-
lations in female rats. All animals except the intact group (no 
estrogen and no stereotaxic injection) received subcutane­
ous estrogen for 30 days, and the groups which received 
RAd-IGF-l or RAd expressing green fluorescent protein (con­
trol) were additionally treated with the appropriate vectors 
on experimental day 0. The RAd-IGF-l group showed a sig­
nificant decrease in serum growth hormone and prolactin 
levels and lactotrope and somatotrope cell size induced by 
estrogen treatment. Cell density was not affected by 7 days 
of IGF-I gene therapy. Estrogen had an inhibitory effect on 
thyrotrope cell density, whereas with RAd-IGF-l there was a 
nonsignificant trend towards restoration of cell density, 
without changes in cell size. RAd-IGF-l treatment decreased
Abbreviations used in this paper
ACTH adrenocorticotropic hormone RAd-GFP recombinant adenoviral vector expressing
FSH follicle-stimulating hormone green fluorescent protein
GH growth hormone RAd-IGF-I recombinant adenoviral vector harboring the
GnRH gonadotropin-releasing hormone cDNA for insulin-like growth factor type I
IGF-I insulin-like growth factor type I RAd-TK recombinant adenoviral vector harboring the
LH luteinizing hormone herpes simplex virus type 1 thymidine kinase
PRL prolactin suicide gene
RAd recombinant adenoviral vector TK thymidine kinase
TSH thyroid-stimulating hormone
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corticotrope cell size without changing cell density. Estro­
gen decreased gonadotrope cell size and density, which was 
reversed by RAd-IGF-l. We conclude that in estrogen-in­
duced pituitary tumors, IGF-I gene therapy has inhibitory ef­
fects on the lactotrope, somatotrope and corticotrope pop­
ulations, while reversing the effect of estrogen on gonado­
tropic Cells. Copyright® 2009 S. Karger AG, Basel
Introduction
Insulin-like growth factor I (IGF-I) is abundant and 
homogeneously distributed throughout the anterior and 
intermediate pituitary lobes [D’Ercole et al., 1984], Al­
though this is compatible with its expression by endo­
crine cells, IGF-I mRNA was detected in cells scattered 
throughout the gland which showed features typical of 
nonendocrine folliculostellate cells [Bach and Bondy, 
1992], The pituitary gland contains several growth fac­
tors [Webster et al., 1989; Halper et al., 1992] that may 
affect the function and proliferation of pituitary cells 
through autocrine or paracrine actions [Houben and De- 
nef, 1994]. Stimulation of sensory neurons prevents apop­
tosis by increasing IGF-I in various tissues [Okajima and 
Harada, 2008].
Estrogens have been shown to rapidly induce lacto­
trope cell tumors within 2-4 weeks in female rats. Estro­
gen exposure has been linked to the formation of prolac­
tinomas in both humans and animals [Sarkar et al., 1982; 
Lloyd, 1983]. Women taking oral contraceptives often 
display increased prolactin (PRL) levels and have an in­
creased incidence of prolactinomas, although not all 
women appear to be equally susceptible to the mitogenic 
effect of estradiol [Shy et al., 1983].
Although estrogen is known to upregulate IGF-I 
mRNA in normal rat pituitaries [Michels et al., 1993], 
large estrogen-induced pituitary adenomas have been re­
ported to possess decreased levels of IGF-I mRNA. Fur­
thermore, partial remission induced by the antiestrogen 
tamoxifen was associated with an increase in the pitu­
itary content of IGF-I mRNA in such adenomas [Hana et 
al., 1998]. It has also been shown that in primary cultures 
of rat lactotropes, estrogen has an antiproliferative action 
in the presence of insulin or IGF-I [Kawashima et al., 
2002; Ishida et al., 2007],
We have recently demonstrated that in vivo delivery of 
the gene for rat IGF-I in estrogen-induced rat prolactino­
mas was able to partially reverse hyperprolactinemia and 
restore lactotrope [Console et al., 2008] and somatotrope 
cell morphology [Console et al., 2009]. In the present 
study, we expanded our investigations into the actions of 
IGF-I gene therapy in estrogen-induced pituitary tumors 
by assessing the effect of this treatment on other endo­
crine pituitary cell populations in these tumors.
Materials and Methods
Adenoviral Vectors
A recombinant adenoviral vector (RAd) harboring the rat 
IGF-I gene (RAd-IGF-I; IGF-I gene kindly donated by Dr. Peter 
Rotwein, Oregon Health Sciences University) was constructed in 
our laboratory by a variant of the 2-plasmid method employing 
the Ad Max" plasmid kit (Microbix, Ontario, Canada) [Herenu et 
al., 2007]. Briefly, the cDNA coding for the rat IGF-I gene (ob­
tained from the mRNA for the IGF-Ib precursor form) [Daugha- 
day and Rotwein, 1989] was excised from the plasmid pBluescript 
KS, subcloned in pCA14 and inserted into the multiple cloning 
site of shuttle pDC515, which contains an expression cassette con­
sisting of the mouse cytomegalovirus promoter and the simian 
virus 40 polyadenylation signal, immediately upstream and 
downstream, respectively, of the multiple cloning site. The second 
plasmid from the kit, the genomic plasmid pBHGfrt(del)El,3 FLP, 
consists of the entire genome of adenovirus 5, with deletions in 
the regions El and E3. In cotransfected HEK293 cells, FLP recom­
binase is readily expressed and efficiently catalyzes the site-di­
rected recombination of the expression cassette of pDC515 into 
pBHGfrt(del)El,3 FLP, thus generating the genome of the desired 
vector RAd-IGF-I. The newly generated RAd was rescued from 
HEK293 cell lysates and plaque purified. It was further purified 
by ultracentrifugation in CsCl gradient. Final virus stocks were 
titrated by a serial-dilution plaque assay.
Another adenoviral vector was constructed in our laboratory 
following the general procedures outlined above and was used as 
a control vector in the gene therapy studies. The vector harbors a 
hybrid gene encoding the Aequorea victoria enhanced green fluo­
rescent protein (EGF) fused to herpes simplex virus type 1 thymi­
dine kinase (TK) (a kind gift from Dr. Jacques Galipeau, McGill 
University, Montreal, Canada). This hybrid gene is driven by the 
mouse cytomegalovirus promoter. The vector (named RAd-GFP) 
was expanded in HEK293 cells and purified and titrated as for the 
RAd-IGF-I vector.
Animals
Young female Sprague-Dawley rats were housed in a tempera­
ture-controlled room (22 ± 2°C) on a 12/12-hour light/dark cy­
cle. Food and water were available ad libitum. All experiments 
with animals were performed according to the Animal Welfare 
Guidelines of the National Institutes of Health (INIBIOLP’s Ani­
mal Welfare Assurance No. A5647-01).
Experimental Design for in vivo IGF-I Gene Therapy
On experimental day -30, all animals but those of the intact 
group (no estrogen and no stereotaxic injection) were subcutane­
ously implanted with Silastic capsules filled with 17[3-estradiol. 
Small blood samples (0.4 ml) were taken from the tail veins of all 
rats on experimental days -25, -15, -10, 0 and +7 for PRL/growth 
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hormone (GH) assays. On experimental day 0, some of the rats 
received bilateral 1.5-pl intrapituitary injections containing 3 X 
109 plaque-forming units of either RAd-GFP or RAd-IGF-I. For 
this purpose, rats were anesthetized with an injection of ketamine 
hydrochloride (40 mg/kg, i.p.) and xylazine (8 mg/kg, i.m.) and 
placed in a stereotaxic frame. In order to access the pituitary re­
gion, the tip of a 26-gauge needle fitted to a 10-pl syringe was 
inserted to the following coordinates relative to the bregma: 5.5 
mm posterior, 9.6 mm ventral and 0.7 mm right and left [Paxinos 
and Watson, 1998]. One week after intrapituitary injection, rats 
were killed by decapitation. Pituitaries were immediately dissect­
ed, fixed and processed for routine histological studies.
Immunohistochemistry
The immunohistochemical procedure was documented previ­
ously [Console et al., 2001]. In brief, pituitary tissues from 5 ani­
mals of each group were fixed in Bouin’s fluid and embedded in 
paraffin. Serial sections of 4 pm were obtained at different levels 
of the blocks following a ventral-to-dorsal sequence. The sections 
were immunostained and then incubated for 1 h at room tem­
perature with the primary antibodies anti-GH, -PRL, -TSH, -ad­
renocorticotropic hormone (ACTH), -follicle-stimulating hor­
mone (FSH) and -luteinizing hormone (LH) (murine, Dako, Cal­
if., USA), diluted 1:100. Thoroughly washed sections were then 
treated for 30 min with a ready-to-use Envision reaction system 
(Dako). The peroxide-sensitive chromogen was diaminobenzi­
dine. In all instances, the specificity of the primary antiserum was 
monitored either by observing its ability to block the immunocy­
tochemical reaction after preabsorption with an excess of the re­
lated antigen or by its replacement with normal rabbit serum or 
phosphate-buffered saline.
Image Analysis
Morphometry was performed as reported in detail previously 
[Console et al., 2002]. In brief, measurements of immunostained 
pituitary cells were performed by means of an image analysis sys­
tem (Imaging Technology, Optimas 5.2). The cells and reference 
area were analyzed in each field on an average of 10 micrographs 
taken from 2 levels. These measurements were recorded and pro­
cessed automatically, and the following parameters were subse­
quently calculated: cell density (number of cells/reference area) 
and cell size (expressed in square micrometers). The reference 
area represents the total area throughout which the cells were 
scored. The number of cells (cell density) was calculated by divid­
ing the immunostained area of the pituitary tissue by the mean 
individual cell area. For this parameter, 100 cells were recorded 
in each field.
Hormone Assays
Serum levels of GH and PRL were measured by a specific ra­
dioimmunoassay using rat materials provided by Dr. A.F. Parlow 
(Pituitary Hormones and Antisera Center, UCLA Medical Cen­
ter, USA). Iodination grade hormones were radiolabeled by the 
Iodo-Gen-’ method and purified on PD-10 Sephadex-’ G-25 M 
columns (Pharmacia, Uppsala, Sweden) equilibrated with 0.01 M 
phosphosaline (pH 7.6). A 1/10 goat antirabbit IgG in 0.9% NaCl 
was used to separate bound from free hormone. Serum concen­
trations of GH and PRL were expressed in terms of NHPP rGH- 
RP-2 and rPRL-RP-3.
Statistical Analysis
Analysis of variance was used to evaluate group differences. 
Tukey’s method was chosen as a post hoc test.
Results
Effect ofIGF-I Gene Therapy on Pituitary Morphology 
The estrogen treatment induced a significant increase 
in pituitary size (data not shown). The impact of intrapi­
tuitary injection of RAd-IGF-I on the endocrine cell pop­
ulations of the adenomas was already evident when im- 
munohistochemically stained pituitary sections were 
qualitatively assessed (fig. 1, 2).
Morphometric assessment revealed that the lactotrope 
population underwent a significant (p < 0.01) increase in 
cell density in rats that received estrogen but no vector 
compared to the intact animals (32.5 ± 2 vs. 19.1 ± 3). 
Seven days of RAd-IGF-I gene therapy did not affect lac­
totrope cell density in estrogen-treated animals com­
pared to animals treated with RAd-GFP (31.6 ± 1.1 vs. 
33.8 ± 3), but pituitary adenomas in estrogen-treated an­
imals showed a significant (p < 0.01) increase in lacto­
trope cell size as compared with their intact counterparts 
(60.1 ± 1.5 vs. 39.4 ± 0.5 pm2). Seven days of IGF-I gene 
therapy significantly (p < 0.01) reversed this change [43.2 
± 0.5 pm2 (estrogen + RAd-IGF-I) vs. 59.2 ± 1.5 pm2 
(estrogen + RAd-GFP)] (fig. 3).
In quantitative terms, morphometric analysis revealed 
that the somatotrope cells in estrogen-treated rats with­
out stereotaxic injections showed a significant (p < 0.01) 
increase in cell size as compared with intact controls (59.9 
± l.lvs.40.6± 1.3 pm2) and had a significant (p< 0.01) 
decrease in cell density compared to intact animals (9.6 
± 0.1 vs. 18.2 ± 1.5). Treatment of pituitary adenomas 
with RAd-IGF-I induced a significant (p < 0.05) decrease 
in cell size compared to estrogen + RAd-GFP treatment 
(53.5 ± 1.3 vs. 59.6 ± 1.2 pm2), but no changes were de­
tected in cell density as compared with RAd-GFP-inject- 
ed animals (11.3 ± 0.7 vs. 10.1 ± 0.1; fig. 3).
The thyrotrope population in rats treated with estro­
gen without stereotaxic injection did not show significant 
changes in TSH cell size (72.7 ± 2.7 vs. 76.3 ± 0.7 pm2) 
but showed a significant (p < 0.01) decrease in cell den­
sity compared to intact animals (0.3 ± 0.1 vs. 3.1 ± 0.2). 
Treatment of pituitary adenomas with RAd-IGF-I in­
duced a nonsignificant increase in TSH cell density (0.5 
± 0.1 vs. 0.3 ± 0.1) without changes in TSH cell size (67.5 
± 3.8 vs. 70.4 ± 1.9 pm2) compared to treatment with 
RAd-GFP (fig. 3).
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Fig. 1 . Effect of IGF-I gene therapy on PRL, GH and TSH cell populations of pituitary adenomas. Representa­
tive fields of specifically immunostained cells from the pituitary gland of an intact rat, an animal which received 
estrogen for 4 weeks and RAd-GFP during the last experimental week (E2 + RAd-GFP) and an animal which 
received estrogen for 4 weeks and RAd-IGF-I during the last experimental week (E2 + RAd-IGF-I). Envision 
system peroxidase. Bar = 45 pm.
The corticotrope population underwent a significant 
(p < 0.01) decrease in cell density in rats treated with es­
trogen without stereotaxic injection (1.9 ± 0.1 vs. 3.2 ± 
0.1) but did not show any changes in cell size (47 ± 2.3 vs. 
51.3 ± 0.6 pm2) compared to intact animals. Treatment 
of pituitary adenomas with RAd-IGF-I induced a signifi­
cant (p < 0.05) decrease in ACTH cell size (38.6 ± 2 vs. 
46.5 ± 1 |Jim2), but no changes were detected in cell den­
sity compared to Rad-GFP (1.8 ± 0.1 vs. 2 ± 0.1; fig. 4).
Morphometric analysis revealed that the gonadotrope 
cells immunostained by anti-FSH antibody in rats treated 
with estrogen without stereotaxic injection presented a 
significant (p < 0.01) decrease in cell size (62.4 ±1.6 vs. 
88 ± 0.1 pm2) and cell density (0.9 ± 0.1 vs. 4.1 ± 0.2) 
as compared with intact controls. RAd-IGF-I induced a 
significant (p< 0.01) increase in cell size (85 ± 3.4vs.61.4 
± 1.5 pm2) and cell density (1.7 ± 0.2 vs. 0.9 ± 0.1; p< 
0.01) as compared with RAd-GFP-injected animals 
(fig- 4).
The gonadotrope cells immunostained by anti-LH an­
tibody in rats treated with estrogen without stereotaxic 
injection showed a significant (p < 0.05) decrease in cell 
size (69.6 ± 0.4 vs. 79 ± 1.7 pm2) and cell density (3.1 ± 
0.1 vs. 6.2 ± 0.1; p < 0.01) as compared with intact con­
trols. RAd-IGF-I induced a significant (p < 0.01) increase 
in cell size (90.7 ±1.6 vs. 70.4 ±1.7 pm2) and cell den-
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Fig. 2. Effect of IGF-I gene therapy on ACTH, FSH and LH cell populations of pituitary adenomas. Representa­
tive fields of specifically immunostained cells in the pituitary gland of an intact rat, an animal which received 
estrogen for 4 weeks and RAd-GFP during the last experimental week (E2 + RAd-GFP) and an animal which 
received estrogen for 4 weeks and RAd-IGF-I during the last experimental week (E2 + RAd-IGF-I). Envision 
system peroxidase. Bar = 45 pun.
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sity (4.5 ± 0.1 vs. 3.2 ± 0.1; p < 0.05) as compared with 
RAd-GFP-injected animals (fig. 4).
Effect of Chronic Estrogen and Intrapituitary Tumor
IGF-I Gene Therapy on Serum PRL and GH Levels
Estrogen administration induced marked hyperpro­
lactinemia in the carrier animals. Seven days after ste­
reotaxic intrapituitary injection of RAd-IGF-I but not 
RAd-GFP, a significant (p < 0.01) fall in serum PRL oc­
curred in the estrogen-treated rats (138 ± 22 vs. 260 ± 
57 ng/ml). Nevertheless, serum PRL in the RAd-IGF-I- 
treated rats remained higher than in the intact rats (ta­
ble 1).
Serum GH was higher (p < 0.01) in estrogen-treated 
rats versus intact controls (141 ± 14 vs. 24 ± 7 ng/ml) at 
7 days. In rats carrying estrogen-induced adenomas, 
RAd-IGF-I injection induced a significant (p < 0.05) re­
duction in serum GH with respect to RAd-GFP-injected 
animals (95 ± 8 vs. 140 ± 10 ng/ml; table 2).
Discussion
Although important advances have been made in the 
treatment of pituitary tumors with surgery and radio­
therapy as well as pharmacological approaches, a fully
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Fig. 3. Effect of IGF-I gene therapy on cell density (CD) and cell size (CS) of lactotropes (PRL cells), somatotropes 
(GH cells) and thyrotropes (TSH cells) in the pituitaries of an intact animal and animals treated with estrogen only 
(E2 only) or estrogen plus RAd-GFP (E2 + RAd-GFP) (control treatments) or IGF-I gene therapy (E2 + RAd-IGF-I). 
Columns represent mean values and bars above columns represent SEM values. Five pituitaries per group were as­
sessed. * p < 0.05, ** p < 0.01 compared to the intact group.
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Fig. 4. Effect of IGF-I gene therapy on cell density (CD) and cell size (CS) of corticotropes (ACTH cells) and 
gonadotropes (FSH and LH cells) in the pituitaries of an intact animal and animals treated with estrogen only 
(E2 only) or estrogen plus RAd-GFP (E2 + R Ad-GFP) (control treatments) or IGF-I gene therapy (E2 + R Ad-IGF- 
I). Columns represent mean values and bars above columns represent SEM values. Five pituitaries per group 
were assessed. * p < 0.05, ** p < 0.01 compared to the intact group.
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Table 1. Effect of chronic estrogen and intrapituitary tumor IGF- 
I gene therapy on serum PRL levels
Time point Intact E2 only e2 +
RAd-GFP
e2 +
RAd-IGF-I
-25 days 90 ±14 73 ± 16 76 ±24 82 ±7
-15 days 76 ±14 80± 13 151 ±24 78 ± 15
-10 days 88 ±20 180 ±45* 197±22 190 ±24
0 day 59 ±18 347 ±50* 189 ±58 241 ±40
+7 days 65 ± 12 308 ±60* 260 ±57 138 ±22*
Serum PRL (ng/ml) was measured in blood samples taken se­
rially from experimental day -25 to experimental day +7. The 
number of rats used was 5 for all groups. E2 = Estrogen. * p < 0.01 
(intact vs. E2 only and E2 + RAd-GFP vs. E2 + RAd-IGF-I).
Time point Intact 17 only 17 + 17 +
RÀd-GFP RAd-IGF-I
Table 2. Effect of chronic estrogen and intrapituitary tumor IGF- 
I gene therapy on serum GH levels
-25 days 33 ±6 55±4 48 ± 16 49 ±5
-15 days 43 ±9 84 ±10* 93± 12 81±4
-10 days 29 ±7 93 ±21** 116 ± 13 114± 11
0 day 42 ±5 152 ±15** 159 ± 18 156 ± 9
+7 days 24 ±7 141±14** 140 ± 10 95 ±8*
Serum GH (ng/ml) was measured in blood samples taken seri­
ally from experimental day -25 to experimental day +7. The num­
ber of rats used was 5 for all groups. E2 = Estrogen. * p < 0.05, 
** p < 0.01 (intact vs. 17 only and 17 + RAd-GFP vs. 17 + RAd- 
IGF-I).
satisfactory therapy is not yet available [Shimon and 
Melmed, 1998]. In this context, gene therapy appears to 
be a potentially useful alternative for the treatment of pi­
tuitary tumors. Early studies showed that a herpes sim­
plex virus type 1-derived vector was highly effective in 
vivo for gene transfer in rat pituitary prolactinomas [Bo- 
lognani et al., 2001]. An adenoviral vector harboring the 
herpes simplex virus type 1 TK suicide gene under the 
control of the human cytomegalovirus promoter (RAd- 
TK) was used to transfer the TK gene to GH3 and AtT2o 
rodent pituitary tumor cells. Incubation of RAd-TK- 
treated GH3 and AtT2o cells with the prodrug ganciclovir 
(which becomes toxic after phosphorylation by viral TK) 
caused significant destruction of the cultures [Windeatt 
et al., 2000]. In the same study, estrogen/sulpiride-in- 
duced rat prolactinomas were stereotaxically injected 
with the same RAd-TK. Subsequent injection of the host 
animals with 2 daily intrapituitary doses of ganciclovir 
(25 mg/kg) for 7 days succeeded in partially reducing tu­
mor size and serum PRL levels. Another type of gene 
therapy strategy for the treatment of pituitary cancer is 
that based on the transfer of a gene(s) with the ability to 
rescue the normal phenotype of tumor cells. This ap­
proach has been implemented in mice heterozygous for 
the retinoblastoma tumor suppressor gene (Rb!/ mice), 
which develop and succumb to characteristic pituitary 
intermediate-lobe melanotrope tumors [Hu et al., 1994],
Our own work reveals that trophic factor gene therapy 
may constitute a suitable alternative to suicide gene ther­
apy for the treatment of pituitary adenomas. In the pres­
ent study, we confirmed that IGF-I gene therapy in estro­
gen-induced pituitary tumors partially reduced the 
marked hyperprolactinemia of the animals and also 
tended to reverse phenotype changes in the lactotrope 
population [Console et al., 2008]. The mechanism by 
which pituitary overexpression of IGF-I inhibits lacto­
tropic cell growth and PRL secretion is not clear. Al­
though estrogen is known to increase pituitary expres­
sion of IGF-I mRNA, it also increases the expression of 
IGF-binding protein 2 mRNA [Michels et al., 1993].
Our findings show that IGF-I gene therapy in estro­
gen-induced pituitary tumors is also beneficial for the so­
matotropic cell population. The fact that IGF-I adminis­
tration did not restore the size of somatotropes reveals the 
importance of locally produced IGF-I, according to Ste- 
faneanu et al. [1999]. Continuous subcutaneous adminis­
tration of IGF-I (7-21 p.g/kg/h) demonstrated that with a 
decrease in the GH levels of greater than 50%, IGF-I sup­
pressed both the number of GH pulses and the GH mass 
secreted per pulse [Ray and Melmed, 1997], In line with 
these results, our data show that intrapituitary RAd-IGF- 
I administration lowers serum levels of GH. The IGF-I 
gene therapy approach described here in an experimental 
rat adenoma model appears to be effective to decrease the 
size of somatotropes and lower the circulating GH levels, 
probably by inhibiting GH secretion.
Daily administration of estradiol benzoate to intact 
male rats led to an increase in circulating TSH after 7 
days of treatment, without alteration of the basal level or 
the TSH pituitary content [De Lean and Labrie, 1977], 
Estradiol is an important mitogen for thyrocytes in rats, 
as it enhances the action of TSH and has an independent 
stimulatory effect on proliferation [Banu et al., 2002], 
Our data also suggest that RAd-IGF-I tends to restore cell 
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density, without changing cell size. The stimulatory ef­
fect of IGF-I in our prolactinomas is in line with reports 
in thyroid cells, where IGF-I has been found to potentiate 
TSH-induced proliferation in vitro [Kimura et al., 2001]. 
In the thyrocyte milieu, this stimulatory action of IGF-I 
may lead to a potentiation of TSH signaling [Kimura et 
al., 2001]. Moreover, Chandrashekar and Bartke [2003] 
speculated on the role of the IGF system in determining 
gender-related differences in thyroid disease.
In female rats, estradiol administration decreases the 
ACTH response to stress [Young et al., 2001]. These re­
sults are consistent with our results, which showed an 
inhibitory effect of estrogen on the corticotrope popula­
tion. IGF-I seems to be produced constitutively in ACTH 
cells, possibly indicating its particular importance in the 
stress response. IGF-I from endocrine cells may control 
hormone synthesis and release in an autocrine-paracrine 
manner as well as prevent apoptosis and stimulate prolif­
eration [Eppler et al. 2007], In the present study, treat­
ment with RAd-IGF-I induced a significant decrease in 
ACTH cell size without changes in the cell density com­
pared to estrogen + Rad-GFP treatment. These data agree 
with the findings of Van Wijk et al. [1998], who reported 
that intrapituitary IGF-I does not have growth-stimulat­
ing effects on canine corticotropic tumor cells.
The biosynthesis and release of gonadotropin-releas­
ing hormone (GnRH) are under complex excitatory and 
inhibitory control by a number of paracrine factors, in­
cluding IGF-I, which can modify GnRH synthesis and 
actions on gonadotropes [Chandrashekar and Bartke, 
2003]. Tilemanset al. [1992] showed that the development 
of PRL-, GH- and ACTH-containing cells in the anterior 
pituitary of the rat is modulated by GnRH and that this 
action is mediated by specific growth factors released by 
gonadotropes.
Estrogen-induced changes in the pars distalis proteome 
may be associated with effects on gonadotropes related to 
negative feedback or associated with other pituitary cells 
[Blake et al., 2005]. Our data show that estrogen treatment 
had an inhibitory effect on the gonadotrope population, 
with a decrease in the cell size and cell density.
Incubation of pituitary cells from salmon with IGF-I 
for 7 or 10 days resulted in significantly higher FSH re­
lease and remaining cell content of FSH and LH [Baker 
et al., 2000], which indicates that the stimulatory effect of 
IGF-I on LH synthesis is exerted through a specific in­
crease in the transcription level of the [3 subunit in Atlan­
tic salmon [Schmitz, 2004]. IGF-I has different effects on 
gonadotropins from human anterior pituitary adenomas, 
stimulating intact FSH, inhibiting or having no effect on 
intact LH in vitro and increasing both the viability and 
number of tumorous glycoprotein-secreting cells enter­
ing the S phase of proliferation [Atkin et al., 1993].
Estradiol and IGF-I may exert antiapoptotic effects 
and thus possibly control the size of gonadotropes 
[Melamed et al., 1999]. In our group of animals treated 
with estrogen + RAd-IGF-I, but not those treated with 
estrogen + Rad-GFP, this decrease in gonadotrope cell 
size and cell density was reversed, thus confirming the 
restorative effect of transgenic IGF-I on estrogen-in­
duced pituitary tumors.
We conclude that IGF-I gene therapy has an overall 
beneficial effect on estrogen-induced pituitary tumors. It 
remains to be determined whether IGF-I may have simi­
lar beneficial effects on other types of pituitary adeno­
mas. If so, IGF-I gene therapy might emerge as an effec­
tive adjuvant to conventional therapies (in particular, 
pituitary surgery) for the treatment of human pituitary 
tumors [Rodríguez et al., 2009].
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